Cullinan Oncology LLC

NASDAQ CGEM

Data sourced from

and

Download Data

Cullinan Oncology LLC Book Value Per Share for the year ending December 31, 2023: 10.92

Cullinan Oncology LLC Book Value Per Share is 10.92 for the year ending December 31, 2023, a -4.81% change year over year. The book value per share represents the net value of a company allocated to each outstanding share of common stock. It is calculated by dividing shareholders' equity by the weighted average number of shares outstanding. The book value per share provides insight into the intrinsic value of a company's shares and can be used to assess the relative value of a stock compared to its market price.

Cullinan Oncology LLC Book Value Per Share for the year ending December 31, 2022 was 11.47, a 20.24% change year over year.
Cullinan Oncology LLC Book Value Per Share for the year ending December 31, 2021 was 9.54, a 634.73% change year over year.
Cullinan Oncology LLC Book Value Per Share for the year ending December 31, 2020 was -1.78, a 15.27% change year over year.
Cullinan Oncology LLC Book Value Per Share for the year ending December 31, 2019 was -2.11, a -16.76% change year over year.

NASDAQ: CGEM

Cullinan Oncology LLC

CEO	Mr. Nadim Ahmed
IPO Date	Jan. 8, 2021
Location	United States
Headquarters	One Main Street, Cambridge, MA, United States, 02142
Employees	85
Sector	Healthcare
Industry	Biotechnology

Description

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Key trends